Head to Head Review: Response Genetics (OTCMKTS:RGDXQ) vs. Cardio Diagnostics (NASDAQ:CDIO)

Response Genetics (OTCMKTS:RGDXQ) and Cardio Diagnostics (NASDAQ:CDIO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, analyst recommendations and risk.

Profitability

This table compares Response Genetics and Cardio Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Response Genetics	N/A	N/A	N/A
Cardio Diagnostics	-22,777.20%	-258.85%	-191.20%

Earnings & Valuation

This table compares Response Genetics and Cardio Diagnostics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Response Genetics	N/A	N/A	N/A	N/A	N/A
Cardio Diagnostics	$35,688.00	300.74	-$8.38 million	N/A	N/A

Response Genetics has higher earnings, but lower revenue than Cardio Diagnostics.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Response Genetics and Cardio Diagnostics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Response Genetics	0	0	0	0	0.00
Cardio Diagnostics	0	0	1	0	3.00

Cardio Diagnostics has a consensus target price of $2.00, indicating a potential upside of 653.58%. Given Cardio Diagnostics’ stronger consensus rating and higher probable upside, analysts plainly believe Cardio Diagnostics is more favorable than Response Genetics.

Insider and Institutional Ownership

8.1% of Cardio Diagnostics shares are held by institutional investors. 4.9% of Response Genetics shares are held by company insiders. Comparatively, 22.3% of Cardio Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Cardio Diagnostics beats Response Genetics on 6 of the 9 factors compared between the two stocks.

About Response Genetics

Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.